Amgen NESP Could Expand Treatment Of Pre-Dialysis Patients, Firm Says
Executive Summary
Amgen's erythropoietin successor product NESP could expand red blood cell stimulation to about 70,000 pre-dialysis patients who do not currently receive EPO, the company believes.